ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2471

Oral Glucosamine Sulphate for the Prevention of Knee Osteoarthritis in Overweight Females; The First Ever Preventive Randomized Controlled Trial

Jos Runhaar1, Marienke van Middelkoop1, Max Reijman2, Edwin Oei3, Dammis Vroegindeweij4, Gerjo van Osch2, Bart Koes1 and Sita Bierma-Zeinstra5, 1General Practice, Erasmus MC, Rotterdam, Netherlands, 2Orthopaedics, Erasmus MC, Rotterdam, Netherlands, 3Radiology, Erasmus MC, Rotterdam, Netherlands, 4Radiology, Maasstad Hospital, Rotterdam, Netherlands, 5Orthopaedics and General Practice, Erasmus MC, Rotterdam, Netherlands

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Glucosamine, Osteoarthritis, prevention and randomized trials

  • Tweet
  • Email
  • Print
Session Information

Session Title: Osteoarthritis - Clinical Aspects II: Structural Risks for Osteoarthritis End-points and Potential Treatments

Session Type: Abstract Submissions (ACR)

Background/Purpose: Previous studies showed the largest effects of glucosamine on osteoarthritis (OA) symptoms of the knee joint and when used in an early phase of the disease. The present study evaluates the effect of a tailor made diet and exercise program (DEP) and of oral glucosamine sulphate, in a 2×2 factorial design, on the incidence of knee OA over 2.5 years in a high risk group of overweight, middle-aged females; free of clinical knee OA at baseline (ISRCTN 42823086; financed by The Netherlands Organisation for Health Research and Development). Worldwide, this is the first large RCT on prevention of knee OA. Here we present the results of the glucosamine intervention and the interaction with DEP.

Methods: 50 general practitioners contacted all registered women between 50 and 60 years. In total, 407 women met all inclusion criteria (BMI ≥ 27, no clinical knee OA (ACR criteria), no contraindications to MRI, no rheumatic diseases, no recent glucosamine usage), were invited for baseline measurements and were randomised. All subjects were instructed to dissolve and consume 1500 mg of the distributed study drug (crystalline glucosamine sulphate and placebo) each day, for 2.5 years. Pre-specified primary outcome was incidence of knee OA, defined by incidence of either K&L ≥ 2, joint space narrowing of ≥ 1.0 mm or incident clinical knee OA (ACR criteria).

Results: After 2.5 years of follow-up, forty-three women (11%) were lost to follow-up. Twenty-nine percent of all subjects reported one or more adverse events throughout the study; without difference in frequency between groups (p = 0.23). The interaction term between both interventions on the primary outcome proved to be significant (p = 0.04). Adjusted Generalized Estimated Equations showed no significant effect of glucosamine sulphate within the DEP control group (OR 0.59; 95%CI 0.31-1.12) or within the DEP intervention group (OR 1.44; 95%CI 0.83 – 2.48), for the Intention To Treat population (see table). The difference in direction of the association, however, is notable. Within subjects compliant to the study drug (≥75% of study drug, N = 250), also no significant effects of glucosamine sulphate over placebo were found (OR 0.69, 95%CI 0.32 – 1.52 and OR 1.32, 95%CI 0.70 – 2.51 respectively). Interestingly, among subjects compliant to DEP the interaction effect became stronger (p = 0.01) and, hence, the contrast of the effects in the placebo and glucosamine group more distinct (see table).

Conclusion: Although safe compared to placebo, crystalline glucosamine sulphate was ineffective for the prevention of knee OA in overweight females over 2.5 years of follow-up.

 

 

Baseline characteristics and incident OA figures for Intention To Treat and Per Protocol analyses.

 

Diet & Exercise Program

 

Control group

Intervention group

 

Placebo

Glucosamine

Placebo

Glucosamine

Baseline characteristics

 

 

 

 

N – subjects

102

102

101

102

   Age (yr)

55.7 ± 3.3

55.7 ± 3.1

55.7 ± 3.2

55.7 ± 3.1

   BMI (kg/m2)

32.6 ± 4.3

32.4 ± 4.6

32.3 ± 4.5

32.1 ± 3.7

   Heberden nodes

 

 

 

 

    uni-lateral

15%

16%

12%

12%

    bi-lateral

10%

14%

20%

9%

   Postmenopausal status

70%

68%

66%

67%

N – knees

204

204

202

204

   K&L

 

 

 

 

    grade 0

53%

47%

53%

50%

    grade ≥ 1

46%

53%

46%

50%

   Varus

46%

38%

38%

37%

   Mild symptoms

17%

20%

27%

19%

   Past injury

14%

12%

10%

13%

Incident knee OA (after 2.5 years)

 

 

 

 

ITT

19%

13%

15%

20%

PP glucosamine

21%

17%

18%

24%

PP DEP

19%

13%

9%

23%

PP glucosamine and DEP

21%

17%

7%

24%

ITT: Intention To Treat population (all randomized subjects). PP: Per Protocol population (compliant to intervention). DEP: diet and exercise program


Disclosure:

J. Runhaar,
None;

M. van Middelkoop,
None;

M. Reijman,
None;

E. Oei,
None;

D. Vroegindeweij,
None;

G. van Osch,
None;

B. Koes,
None;

S. Bierma-Zeinstra,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/oral-glucosamine-sulphate-for-the-prevention-of-knee-osteoarthritis-in-overweight-females-the-first-ever-preventive-randomized-controlled-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies